New platform for predictive modelling of cancer signalling: European Consortium “CanPathPro” started

An international group of scientists from 6 countries bring together their expertise to develop a combined experimental and systems biology platform for predictive modelling of cancer signalling. The EU Horizon 2020 funded project, co-ordinated by Alacris Theranostics GmbH, Berlin, will run for 5 years with a budget of almost 11 million euros.

The European Research Consortium CanPathPro now takes a unique approach and brings together classic cancer research with omics data and systems biology tools, to develop and validate a new biotechnological application: a combined systems and experimental biology platform for generating and testing cancer signalling hypotheses in biomedical research.
Previous bioinformatic attempts in this direction have been confined to pattern recognition or, at best, modelling of single pathways. Such approaches often cannot take into account the complexity of living organisms, comprising numerous pathways and their cross-talk. These features are of paramount significance in cancer, where signalling complexity is the major determinant of disease progression and drug response.
To achieve its objective, CanPathPro will develop and refine bioinformatic and experimental tools for the evaluation of systems biology modelling predictions. Components comprise highly defined mouse and organotypic experimental systems, next generation sequencing, quantitative proteomics and a systems biology computational model for data integration, visualisation and predictive modelling.

Read the full press release here: